MAY 20, 2020 12:45 PM EDT | APAC MAY 21, 2020 3:45 PM CST

Comparison of PAM50 Intrinsic Subtype Profiles in Matched Primary & stage IV Breast Cancer Samples from CTC-MBC Trial Shows Shift Towards More Aggressive Subtypes Throughout Tumor Progression

Speaker
  • Professor i Kirurgi, Lund University, Medical Faculty, dept of Clinical Sciences Lund, div of Oncology and Surgery
    Biography
      Lisa Rydén is full professor in Surgery at Lund University and a senior consultant in general surgery at Skåne University Hospital. She was a board member of the strategic cancer area BioCare at Lund University 2012-2019 and is currently a board member of Lund University Cancer Centre. She was appointed a Skou Honarary Professor in cancer research at Århus University, Denmark, in 2019.

      Lisa Rydén wrote her thesis on tamoxifen response in primary breast cancer focusing on predictive tumour features and the work paved the way for forthcoming research in clinically relevant areas of molecular biology. She has been heading a translational research group in breast cancer since 2010 focusing on the importance of tumour progression and prediction of lymph node metastasis. Seven PhD students have graduated based on the program which has been funded by the Swedish Cancer Society and Swedish Research Council among others. She has contributed with > 100 peer-reviewed publications in the field. In 2016 she was awarded the Nordic Medicine Prize in breast cancer research together with Heikki Juensuu and in 2019 Reutersköld´s award in surgical sciences from the Swedish Medical Association.

      Lisa Rydén held the chair of the South Swedish Breast Cancer group between 2009-2018 and was the secretary of the Swedish Breast Cancer Group 2007-2018. In 2015-2019 she also held the chair of the Swedish Society of Breast Surgeons. In all these positions she encouraged and initiated multidisciplinary and translational collaborations aiming at improving breast cancer care and ultimately the outcome and well-being of breast cancer patients. She is also a collaborative member of Early Breast Cancer Trialists' Collaborative Group and International Breast cancer Intervention Study Group.

    Abstract

    At time of diagnosis of metastatic disease, a biopsy of the metastatic lesion is recommended to confirm diagnosis and as a basis for systemic treatment decision. Numerous papers have reported discrepancy between routinely used biomarker status of the primary tumor and corresponding metastases in a relatively large proportion of patients, but less is known about gene expression profiles throughout tumor progression. Differences between biomarker status of the primary tumor lesion and its metastasis could be a major cause of treatment failure, and the molecular alterations that occur during tumor progression are still incompletely described. The main objective of this study was to use tumor specimens collected from a prospective observational trial to determine the PAM50 breast cancer intrinsic subtype in matched pairs of tumor samples from primary tumor (PT), synchronous lymph node metastases (LNMs), and distant metastases (DMs), to investigate if subtype classification changes during tumor progression, and the putative implication of a shift in inherence on prognosis. RNA was isolated from archival formalin-fixed, paraffin-embedded tumor tissue from newly diagnosed metastatic breast cancer patients (N=156) enrolled in the CTC-MBC trial (NCT01322893), and run with the NanoString Breast Cancer 360 assay on the NanoString nCounter Sprint Profiler. PAM50 breast cancer intrinsic subtyping analysis was completed at NanoString, and the statistical analysis at Lund University. Exact McNemar tests and exact tests of symmetry were used to compare subtype inherence at two locations, i.e. matched pairs of PTs and LNMs or DMs. RNA from 143 patients was evaluable. A PAM50 breast cancer intrinsic subtype could be assigned to 124 PT samples, 68 synchronous LNMs and 76 DMs (Table 1), of which 59 and 63 had paired data, respectively. The evidence for a difference in PAM50 breast cancer intrinsic subtype between matched pairs (PT and LNM; PT and DM) was generally strong (Table 2). A PAM50 conversion was seen in 21/59 (36%) cases considering the luminal A vs non-luminal A subtype between matched pairs of PT and LNM, 17/21 (81%) of which changed from luminal A to non-luminal A subtype (P=0.007). In matched pairs of PT and DM a PAM50 conversion was seen in 27/63 (43%) cases comparing the luminal A vs non-luminal A subtype, 25/27 (93%) of which changed from luminal A to non-luminal A subtype (P<0.001). The present study shows that PAM50 breast cancer intrinsic subtype is not stable throughout tumor progression. A significant shift towards a non-luminal A subtype profile was observed in both LNMs and DMs. The shift towards a non-favorable subtype from PT to DM confirms previous data on biomarker status, whereas the significant shift towards a non-luminal A subtype in LNM has to our knowledge not previously been described. Survival analysis is ongoing on the prognostic implication of a shift in PAM50 breast cancer intrinsic subtype.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources